What are the indications for filgrastim?
Category:
medical health
cancer
NEUPOGEN (filgrastim) is approved for 5 indications in the following patient populations:
- Chemotherapy-induced Febrile Neutropenia.
- Acute Myeloid Leukemia.
- Cancer Patients Receiving Bone Marrow Transplant.
- Peripheral Blood Progenitor Cell Collection and Engraftment.
- Severe Chronic Neutropenia.
Herein, when should Neupogen be given?
The recommended dosage of NEUPOGEN for the mobilization of autologous peripheral blood progenitor cells (PBPC) is 10 mcg/kg/day given by subcutaneous injection. Administer NEUPOGEN for at least 4 days before the first leukapheresis procedure and continue until the last leukapheresis.
In this way, when should filgrastim be given?
The manufacturer recommends that the first dose of filgrastim be given no sooner than 24 hours after chemotherapy. Your doctor will discontinue therapy with filgrastim when your white blood cell count has reached acceptable levels.
colony-stimulating factors